TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

This was the stock's fifth consecutive day of gains.

Detailed price information for Harvest Eli Lilly High Income Shares ETF (LLYH-T) from The Globe and Mail including charting and trades.

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Algernon to Acquire NoBrainer - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

CAMPBELL, Calif. (AP) — CAMPBELL, Calif. (AP) — 8x8 Inc. (EGHT) on Monday reported a loss of $5.4 million in its fiscal fourth quarter. On a per-share basis, the Campbell, California-based company ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the ...

Looking ahead, Wall Street forecasts adjusted EPS of $23.21 for fiscal 2025, representing a 78.7% increase from $12.99 in ...

Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chair and ...

Eli Lilly Q4 Presentation In Q4 2024, Eli Lilly's revenue grew 45%, driven by Mounjaro and Zepbound, the company's core weight-loss drugs. Non-incretin revenue grew by 20% compared to Q4 2023.